Department of Structural and Functional Biology, Institute of Biology, University of Campinas--UNICAMP, São Paulo, Brazil.
Immunol Lett. 2013 Jun;153(1-2):50-7. doi: 10.1016/j.imlet.2013.07.004. Epub 2013 Jul 23.
For more than two decades, chloroquine (CQ) was largely and deliberately used as first choice drug for malaria treatment. However, worldwide increasing cases of resistant strains of Plasmodium have hampered its use. Nevertheless, CQ has recently been tested as adjunct therapy in several inflammatory situations, such as rheumatoid arthritis and transplantation procedures, presenting intriguing and promising results. In this review, we discuss recent findings and CQ mechanisms of action vis-à-vis its use as a broad adjunct therapy.
二十多年来,氯喹(CQ)在很大程度上被有意用作治疗疟疾的首选药物。然而,全世界范围内疟原虫耐药株的病例不断增加,这阻碍了其使用。尽管如此,CQ 最近在几种炎症情况下,如类风湿关节炎和移植手术中,作为辅助治疗进行了测试,取得了有趣且有前景的结果。在这篇综述中,我们讨论了最近的发现和 CQ 的作用机制,以及将其作为一种广泛的辅助治疗方法的应用。